Details for Patent: 12,622,904

« Back to Dashboard

Which drugs does patent 12,622,904 protect, and when does it expire?

Patent 12,622,904 protects SUBLOCADE and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 12,622,904

Title:	Buprenorphine dosing regimens
Abstract:	The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
Inventor(s):	Azmi NASSER, Celine M. Laffont, Christian A. HEIDBREDER
Assignee:	Indivior UK Ltd
Application Number:	US19/085,650
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 12,622,904

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-001	Nov 30, 2017		RX	Yes	No						TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER BY ONCE-MONTHLY SUBCUTANEOUS ADMINISTRATION OF BUPRENORPHINE FREE BASE
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes						TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER BY ONCE-MONTHLY SUBCUTANEOUS ADMINISTRATION OF BUPRENORPHINE FREE BASE

International Family Members for US Patent 12,622,904

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015341490
Canada	2965895
Canada	3015557